Background Image
Table of Contents Table of Contents
Previous Page  44 / 66 Next Page
Basic version Information
Show Menu
Previous Page 44 / 66 Next Page
Page Background

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 25, No 6, November/December 2014

294

AFRICA

14. Myers MG. Replacing manual sphygmomanometers with automated

blood pressure measurement in routine clinical practice.

Clin Exp

Pharmacol Physiol

2014;

41

(1): 46–53.

15. Beckett NS, Peters R, Fletcher AE,

et al

. HYVET study group.

Treatment of hypertension in patients 80 years of age or older.

N Engl J

Med

2008;

358

: 2417–2428.

16. Wright JT Jr, Fine LJ, LacklandDT, Ogedegbe G, DennisonHimmelfarb

CR. Evidence supporting a systolic blood pressure goal of less than 150

mmHg in patients aged 60 years or older: the minority view.

Ann Intern

Med

2014;

160

(7): 499–503.

17. South African Dyslipidaemia Guideline Consensus Statement. A joint

statement from the South African Heart Association (SA Heart) and the

Lipid and Atherosclerosis Society of Southern Africa (LASSA)

S Afr

Med J

2012;

102

:177–188.

18. Amod A, Motala A, Levitt N,

et al

.: guideline committee. The 2012

SEMDSA guideline for the management of type 2 diabetes.

J Endocrinol

Metab Diabetes SA

2012;

17

(1): S1–S94.

19. Zanchetti A, Hansson L, Dahlöf B, Julius S, Ménard J, Warnold I,

Wedel H; HOT study group. Benefit and harm of low-dose aspirin in

well-treated hypertensives at different baseline cardiovascular risk.

J

Hypertens

2002;

20

(11): 2301–2307.

20. Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM.

Aliskiren and the calcium channel blocker amlodipine combination as

an initial treatment strategy for hypertension control (ACCELERATE):

a randomised, parallel-group trial.

Lancet

2011;

377

: 312–320.

21. Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS.

Initial combination therapy reduces the risk of cardiovascular events in

hypertensive patients: a matched cohort study.

Hypertension

2013;

61

:

309–318.

22. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness

of fixed-dose combinations of antihypertensive agents: a meta-analysis.

Hypertension

2010;

55

: 399–407.

23. Brewster LM, Seedat YK. Why do hypertensive patients of African

ancestry respond better to calcium blockers and diuretics than to ACE

inhibitors and

β

-adrenergic blockers? A systematic review.

BMC Med

2013;

11

: 141.

24. Herbert CJ, Vidt DG. Hypertensive crisis.

Prim Care

2008;

35

: 478–487.

25. Handler J. Hypertensive urgency.

J Clin Hypertens

2006;

8

: 61–64.

26. Neurological Association of South Africa/South African Medical

Association. Stroke therapy guideline.

S Afr Med J

2000;

90

: 276–306.

27. Chapman N, Dobson J, Wilson S,

et al

. Anglo-Scandinavian cardiac

outcomes trial investigators. Effect of spironalactone on blood pressure

in subjects with resistant hypertension.

Hypertension

2007;

49

: 839–845.

28. Chapman N, Chang CL, Dahlöf B, Sever PS, Wedel H, Poulter NR, on

behalf of the ASCOT investigators. Effect of doxazosin gastrointesti-

nal therapeutic system as third-line antihypertensive therapy on blood

pressure and lipids in the Anglo-Scandinavian cardiac outcomes trial.

Circulation

2008;

118

: 42–48.

29. Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-

Singh K,

et al

. Percutaneous renal denervation in patients with

treatment-resistant hypertension: final 3-year report of the Symplicity

HTN-1 study.

Lancet

2014;

383

: 622–629.

30. Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka

PA; Symplicity HTN-2 investigators. Renal sympathetic denervation

for treatment of drug-resistant hypertension: one-year results from the

Symplicity HTN-2 randomized, controlled trial.

Circulation

2012;

126

:

2976–2982.

31. Bhatt DL, Kandzari DE, O’Neill WW,

et al

. Symplicity HTN-3 investi-

gators. A controlled trial of renal denervation for resistant hypertension.

N Engl J Med

2014;

370

: 1393–1401.

32. Opie LH, Seedat YK. Hypertension in sub-Saharan African popula-

tions.

Circulation

2005;

112

: 3562–3568.

33. Seedat YK. Diabetes mellitus in South African Indians. In: V Mohan

and GHR Rao (eds).

Type 2 Diabetes in South Asians: Epidemiology,

Risk Factors and Prevention.

New Delhi: Jaypee Brothers, 2007: 40–44.

ISBN 81-8061-936-2.

34. Seedat YK. Varying responses to hypotensive agents in different racial

groups, black versus white differences.

J Hypertens

1989;

7

: S15–18.

35. Kostis JB, Kim HJ, Rusnak J,

et al.

Incidence and characteristics of

angioedema associated with enalapril.

Arch Intern Med

2005;

165

:

1637–1642.

36. Sinaiko AR. Hypertension in children.

N Engl J Med

1996;

335

:

1968–1973.

37. Task force on blood pressure control in children. Report of the second

task force on blood pressure control in children, 1987. National Heart,

Lung, and Blood Institute, Bethesda, Maryland.

Pediatrics

1987;

79

:

1–25.

38. Bradshaw D, Steyn K, Levitt N, Nojilana B. Non-communicable diseas-

es – A race against time.

http://www.mrc.ac.za/policybriefs/raceagainst.

pdf (accessed 5th May 2014).

39. Wearne N, Swanepoel CR, Boulle A, Duffield MS, Rayner BL. The

spectrum of renal histologies seen in HIV with outcomes, prognostic

indicators, and clinical correlations.

Nephrol Dial Transplant

2012;

27

(11): 4109–4118.

40. Seaberg EC, Munoz A, Lu M,

et al

. Association between highly active

anti-retroviral therapy in a large in a large cohort of men followed from

1984 to 2003. Multicenter AIDS cohort study.

AIDS

2005;

19

: 953–960.

41. Glesby MJ, Aberg JA, Kendall MA, et al. AIDS clinical trials group

A5159 protocol team. Pharmacokinetic interactions between indinavir

plus ritonavir and calcium channel blockers.

Clin Pharmacol Ther

2005;

78

: 143–153.

42. De Maat M, Ekhart GC, Huitema ADR, Koks CH, Mulder JW, Beijnen

JH. Drug interactions between antiretroviral drugs and co-medicated

agents.

Clin Pharmacokinet

2003;

44

: 223–282.